MedTrace Logo

Indacaterol EfectIveness In COPD Patients With Tuberculosis History

NCT01778062 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2015-10-23

Study results available
· View outcomes & findings →

Summary

This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.

Conditions

  • Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Interventions

DRUG

Indacaterol

Indacaterol 150µg once daily oral inhalation

DRUG

Control

Placebo once daily oral inhalation

Sponsors & Collaborators

Principal Investigators

  • Chul-Gyu Yoo, MD PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01778062 on ClinicalTrials.gov